MARKSANS Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹754.4 Cr
verified against source
Revenue YoY
10.6%
reported change
EBITDA
₹160.7 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Marksans Pharma delivered a 10.6% YoY revenue growth to ₹754.4 crore in Q3 FY26, marking an all-time high quarterly revenue driven by robust US performance and sequential UK recovery. EBITDA expanded 217 basis points to 21.3% margin on the back of raw material softening, favorable product mix, and operating leverage. The US market grew 16.9% to ₹412.4 crore with a strong $220+ million order book, while UK/EU stabilized with new product launches absorbing pricing pressures. Management targets ₹4,000 crore revenue in the next 2-3 years, implying ~18% CAGR from current levels, with Europe positioned as the next growth catalyst through M&A. Gross margins at 58.1% reflect improved product mix, though price erosion in RX segments remains a watch item. The company maintains its debt-free status with ₹824 crore cash for strategic deployment in Europe acquisitions.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated its first milestone target of ₹4,000 crore revenue within the next 2-3 years (FY28-29), driven by current portfolio strength without factoring in new geographies.
- The US order book stands at $220+ million with management targeting to grow it to $300 million by FY28, supporting ~20% US revenue growth trajectory.
- R&D expenditure will remain elevated at 2.5-3% of revenue for the next year, supporting aggressive UK filings (4-5 products/month) and Europe product development.
- Management expects 2026 to be a turning point for Europe with potential closure of 1-2 acquisitions, though deal sizes were not quantified pending advanced-stage discussions.
Risks flagged
- Analyst raised concerns about tariff-related uncertainties affecting US market dynamics in early 2025. Management acknowledged first half headwinds but expressed optimism post trade deal, though did not quantify potential impact if uncertainties resurface.
- Single-digit price erosion continues in RX product segments in both US and UK markets. While new product launches (higher margin) are absorbing some impact, the RX portfolio's larger size in UK means price pressures could persist and limit margin recovery.
- Management flagged that Europe is a cluster of countries requiring country-specific distribution, licenses, and market authorizations. Greenfield expansion and M&A integration complexity could delay revenue visibility beyond stated timelines.
- Goa facility operating at ~50% capacity against ₹800 crore target means fixed cost deleverage is dependent on revenue growth acceleration. Employee cost elevated at 15% of revenue vs historical 13% may pressure margins if capacity ramp delays.
Key quotes
- Our next milestone is 4,000 crores so we are working towards that and then once we cross that then we can talk about the next 5,000 odd crores so we are we are on track where that is concerned and that should be ideally two to three years.
- These gross margins... obviously they've just launched a couple of them right now so it has to take shape... the profitability and the margins are much better on the products that we are launching. It is not so much from a value topline point of view. It's more from a bottom line point of view.
- 2026 will be a turning point where that is concerned. We are quite hopeful that 2026 we may see couple of M&As happening out there in Europe.
Research modules